Start here if you're new
what it is
Sangamo builds 3 gene and cell therapies, including Phase I/II Fabry and Phase III hemophilia A programs.
how it gets paid
Last year Sangamo Therapeutics made $58M in revenue.
what just happened
Revenue hit $25M, but EPS was still -$0.33.
At a glance
C++ balance sheet — some cracks in the foundation
45/100 earnings predictability — expect surprises
-$0.49 fy2024 eps est
$58M fy2024 rev est
n/a operating margin
xvary composite: 34/100 — weak
What they do
Sangamo builds 3 gene and cell therapies, including Phase I/II Fabry and Phase III hemophilia A programs.
You are not buying a sales machine. You are buying 3 clinical shots: ST-920 in Phase I/II, TX200 in Phase I/II, and SB-525 in Phase III. Phase I/II means early human testing; Phase III means the expensive proof step. That pipeline is the moat, and it is also the gamble.
How they make money
$58M
annual revenue
total revenue
$58M
n/a
The products that matter
gene therapy candidate
isaralgagene civaparvovec
rolling BLA started dec 2025
this is the lead asset and the nearest shot at turning the story from research spend into a regulatory event. december 2025 matters because it moved the program into a formal FDA filing process.
lead program
preclinical and clinical assets
giro-vec & STAC-BBB
positive update oct 2024
these programs helped drive a stock surge after positive updates in october 2024. they matter because SGMO needs more than one asset, but they are still earlier and less financeable than the lead filing.
earlier-stage optionality
Key numbers
$58M
annual revenue
You are paying $135M for a company with $58M of yearly sales. That is 2.3 times sales before the clinical risk premium.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. For every $1 of revenue, Sangamo loses about $1.80 in operations. That is why the business still needs outside capital.
$25M
long-term debt
Debt is only $25M, but that still matters when revenue is $58M and losses are this wide.
1.35
beta
The stock has moved about 35% more than the market in theory. On a $0.39 stock, that means big swings from tiny headlines.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $25M (16% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for SGMO right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $25M, but EPS was still -$0.33.
Revenue jumped 4,259% vs. prior year to $25M, but the company stayed deeply unprofitable. Wall Street’s trailing revenue is still $58M, so this is a small base with big swings.
$25M
revenue
-$0.33
eps
+4259%
revenue Vs. last year
the number that mattered
The $25M quarter matters because it is the first number here that looks like product demand, not just science risk.
source: company earnings report, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
SGMO's risk stack is unusually blunt: a $0.39 stock has until april 27, 2026 to solve a $1.00 Nasdaq problem while the lead filing is still a filing, not an approval.
med
Nasdaq minimum bid compliance
The stock trades at $0.39, or 61% below Nasdaq's $1.00 minimum bid requirement. The current extension runs to april 27, 2026.
Miss that line and the company likely faces a reverse split, delisting pressure, or both. None of those outcomes help funding confidence.
med
Lead-program regulatory slippage
Isaralgagene civaparvovec entered a rolling BLA in december 2025, but there is still no approval and no approved commercial product behind it.
If the filing stalls, 100% of the current revenue mix remains collaboration, license, grant, and other revenue rather than product revenue.
med
Funding opacity and dilution risk
The company referenced a preliminary cash position as of dec 31, 2025, but the amount was not available in the source set. Pair that with a C++ balance sheet and $25M of long-term debt, and runway becomes a live question.
When investors cannot see the cash clearly, they usually assume new capital is coming. For a $121.7M company, that can get expensive fast.
med
Short sentiment and trading instability
Short interest increased as of february 13, 2026, and price stability sits at 5 / 100. This already trades like a stressed security.
That setup can amplify both good and bad headlines, which is great if you are right and punishing if you are early.
The key math is simple: a sub-$1 stock, a non-commercial revenue base, and an unquantified cash figure leave very little margin for delay.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
Nasdaq compliance deadline
april 27, 2026 is the date that matters. SGMO needs the stock back above $1.00 or the listing issue becomes a capital-markets problem.
catalyst
Rolling BLA progress for isaralgagene civaparvovec
The filing started in december 2025. Completion timing and FDA feedback now matter more than most headline revenue numbers.
execution
Finance leadership transition
A finance-team change in february 2026 is worth tracking because weak balance sheets do not get the luxury of messy execution.
metric
Whether revenue becomes less grant-driven
Today the reported mix is 56.7% collaboration and license revenue plus 43.3% grant and other revenue. Any shift toward commercial revenue would change the story fast.
Analyst rankings
earnings predictability
45 / 100
in human-speak, analysts do not have a clean quarter-to-quarter model here because grants, milestones, and clinical headlines do not show up on a tidy schedule.
risk profile
4
Risk rank 4 means safer than only about 20% of stocks in the dataset. That is what a sub-$1 clinical biotech usually looks like.
source: institutional data
Institutional activity
institutional ownership data for SGMO is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$0
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive